Eric Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Wong has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Olivia Catherine Smibert
Department of Infectious Diseases and Immunology Austin Health Melbourne Victoria Australia
2 shared publications - Abby P. Douglas
National Centre for Infections in Cancer, Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
1 shared publication - Andrea S. Henden
Department of Haematology and Bone Marrow Transplantation Cancer Care Services, Royal Brisbane and Women's Hospital Brisbane Queensland Australia
1 shared publication - Andrew Grigg
Department of Clinical Haematology Austin Health Melbourne Victoria Australia
1 shared publication - Andrew P. Gador-Whyte
The University of Melbourne
1 shared publication - David Jonathan Gottlieb
Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Wiley in British Journal of Haematology
Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation
Summary: Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T‐cell exhaustion. This prospective phase I study evaluated the safety and efficacy of the PD‐1 inhibitor, nivolumab, in enhancing GVT post‐alloHSCT and explored the impact of baseline T‐cell phenotypes on clinical outcomes. Fourteen patients with relapsed/refractory haematological malignancies post‐alloHSCT received nivolumab every 2 weeks for up to 48 weeks. Six achieved complete remission, all with chronic lymphoid malignancies. Patients with myeloid malignancies or acute lymphoblastic leukaemia had inferior progression‐free survival (4.3 vs. 11.7 months, p < 0.05) and overall survival (43.6 months vs. undefined, p < 0.05) than those with chronic lymphoid malignancies. Nine serious adverse events occurred, including four dose‐limiting toxicities due to graft‐versus‐host disease (GVHD) or pneumonitis. Patients who developed GVHD had higher T‐cell activation at baseline and achieved early clinical responses. These findings confirm that nivolumab can promote GVT post‐alloHSCT, particularly in lymphoid disorders. Baseline immunophenotype (effector memory T cells, Human Leukocyte Antigen – DR isotype [HLA‐DR]) and gene expression (granzyme A [GZMA], granzyme B [GZMB], perforin [PRF1]) can be used as biomarkers to help identify patients most likely to benefit from salvage checkpoint inhibition.
- 16 October 2026
- Published by Wiley in British Journal of Haematology
Open AccessProspective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation
Summary: Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T‐cell exhaustion. This prospective phase I study evaluated the safety and efficacy of the PD‐1 inhibitor, nivolumab, in enhancing GVT post‐alloHSCT and explored the impact of baseline T‐cell phenotypes on clinical outcomes. Fourteen patients with relapsed/refractory haematological malignancies post‐alloHSCT received nivolumab every 2 weeks for up to 48 weeks. Six achieved complete remission, all with chronic lymphoid malignancies. Patients with myeloid malignancies or acute lymphoblastic leukaemia had inferior progression‐free survival (4.3 vs. 11.7 months, p < 0.05) and overall survival (43.6 months vs. undefined, p < 0.05) than those with chronic lymphoid malignancies. Nine serious adverse events occurred, including four dose‐limiting toxicities due to graft‐versus‐host disease (GVHD) or pneumonitis. Patients who developed GVHD had higher T‐cell activation at baseline and achieved early clinical responses. These findings confirm that nivolumab can promote GVT post‐alloHSCT, particularly in lymphoid disorders. Baseline immunophenotype (effector memory T cells, Human Leukocyte Antigen – DR isotype [HLA‐DR]) and gene expression (granzyme A [GZMA], granzyme B [GZMB], perforin [PRF1]) can be used as biomarkers to help identify patients most likely to benefit from salvage checkpoint inhibition.
- Open Access
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
Open AccessANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- 22 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70222
Preventing Cat‐Astrophe: Toxoplasma Seroprevalence and Prophylaxis Adherence After Allogeneic Stem Cell Transplant
- 22 May 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70222
Preventing Cat‐Astrophe: Toxoplasma Seroprevalence and Prophylaxis Adherence After Allogeneic Stem Cell Transplant
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
A Rare Case of Renal Failure Caused by T‐Cell Prolymphocytic Leukaemia Infiltration
T‐cell prolymphocytic leukaemia (T‐PLL) is an aggressive and rare post‐thymic T cell malignancy, highly refractory to conventional cytotoxic chemotherapeutics. While extranodal involvement is common, solid organ invasion is rare. We present the case of a 76‐year‐old man who developed acute renal failure secondary to T‐PLL renal infiltration. On day four of his admission, prior to commencing alemtuzumab, his creatinine rose from 133 μmol/L to 390 μmol/L, with anuria. Renal biopsy demonstrated an infiltrate of monomorphic, mononuclear cells positive for a STAT5B mutation, consistent with T‐PLL infiltration. He required haemodialysis, but was treated with pulsed methylprednisolone and alemtuzumab, with excellent renal recovery, although remission was not achieved. This case demonstrates that renal leukaemic infiltration must be considered in T‐PLL patients with rapidly progressive renal failure, and that solid organ invasion should not contraindicate timely commencement of T‐PLL‐directed therapy with alemtuzumab.
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
Open AccessA Rare Case of Renal Failure Caused by T‐Cell Prolymphocytic Leukaemia Infiltration
T‐cell prolymphocytic leukaemia (T‐PLL) is an aggressive and rare post‐thymic T cell malignancy, highly refractory to conventional cytotoxic chemotherapeutics. While extranodal involvement is common, solid organ invasion is rare. We present the case of a 76‐year‐old man who developed acute renal failure secondary to T‐PLL renal infiltration. On day four of his admission, prior to commencing alemtuzumab, his creatinine rose from 133 μmol/L to 390 μmol/L, with anuria. Renal biopsy demonstrated an infiltrate of monomorphic, mononuclear cells positive for a STAT5B mutation, consistent with T‐PLL infiltration. He required haemodialysis, but was treated with pulsed methylprednisolone and alemtuzumab, with excellent renal recovery, although remission was not achieved. This case demonstrates that renal leukaemic infiltration must be considered in T‐PLL patients with rapidly progressive renal failure, and that solid organ invasion should not contraindicate timely commencement of T‐PLL‐directed therapy with alemtuzumab.
- 28 December 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (2) , e14429
Latent Tuberculosis Infection Amongst Allogeneic Hematopoietic Stem Cell Transplant Recipients: The Impact of Routine Pretransplant Review by a Transplant Infectious Diseases Physician
Background: Identifying patients with latent tuberculosis infection (LTBI) is challenging. This is particularly true amongst immunocompromised hosts, in whom the diagnostic accuracy of available tests is limited. The authors evaluated the impact of routine pretransplant review by a transplant infectious diseases (TID) physician on LTBI screening in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Methods: Adult patients who received an alloHSCT between January 2018 and December 2022 were eligible for inclusion. Data were retrospectively extracted from patient records. Participants were dichotomized into those that had a routine pretransplant review with a TID physician and who that did not. Results: Of the 116 participants included, 61.2% had a documented TID review. This intervention was associated with more frequent initiation of LTBI treatment (8.5% vs. 0.0%) and a tendency for LTBI treatment to be initiated in the absence of immunodiagnostic criteria (7.1% vs. 0.0%). A case of LTBI reactivation occurred in each group. Conclusion: Routine pretransplant review by TID physicians improved the recognition of risk factors for LTBI and increased the initiation of LTBI treatment in patients with a high pretest probability of LTBI. Further research is needed to evaluate the utility of routine pretransplant TID review and to determine the optimal strategy for preventing LTBI reactivation amongst alloHSCT recipients in low‐endemic settings. image
- 28 December 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (2) , e14429
Latent Tuberculosis Infection Amongst Allogeneic Hematopoietic Stem Cell Transplant Recipients: The Impact of Routine Pretransplant Review by a Transplant Infectious Diseases Physician
Background: Identifying patients with latent tuberculosis infection (LTBI) is challenging. This is particularly true amongst immunocompromised hosts, in whom the diagnostic accuracy of available tests is limited. The authors evaluated the impact of routine pretransplant review by a transplant infectious diseases (TID) physician on LTBI screening in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Methods: Adult patients who received an alloHSCT between January 2018 and December 2022 were eligible for inclusion. Data were retrospectively extracted from patient records. Participants were dichotomized into those that had a routine pretransplant review with a TID physician and who that did not. Results: Of the 116 participants included, 61.2% had a documented TID review. This intervention was associated with more frequent initiation of LTBI treatment (8.5% vs. 0.0%) and a tendency for LTBI treatment to be initiated in the absence of immunodiagnostic criteria (7.1% vs. 0.0%). A case of LTBI reactivation occurred in each group. Conclusion: Routine pretransplant review by TID physicians improved the recognition of risk factors for LTBI and increased the initiation of LTBI treatment in patients with a high pretest probability of LTBI. Further research is needed to evaluate the utility of routine pretransplant TID review and to determine the optimal strategy for preventing LTBI reactivation amongst alloHSCT recipients in low‐endemic settings. image